513 related articles for article (PubMed ID: 35836112)
1. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
2. The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma.
Yao K; Zhang R; Li L; Liu M; Feng S; Yan H; Zhang Z; Xie D
Front Immunol; 2023; 14():1181370. PubMed ID: 37600770
[TBL] [Abstract][Full Text] [Related]
3. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma.
Wang H; Wang W; Wang Z; Li X
Front Immunol; 2023; 14():1291859. PubMed ID: 38143740
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer.
Han C; Deng Y; Yang B; Hu P; Hu B; Wang T; Liu J; Xia Q; Liu X
Front Immunol; 2023; 14():1126902. PubMed ID: 36891298
[TBL] [Abstract][Full Text] [Related]
7. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract][Full Text] [Related]
8. A N
Mei W; Jia X; Xin S; Liu X; Jin L; Sun X; Zhang JX; Zhang B; Yang G; Chen P; Ye L
J Oncol; 2022; 2022():8604216. PubMed ID: 35602299
[TBL] [Abstract][Full Text] [Related]
9. Characterization of metabolism-associated molecular patterns in prostate cancer.
Yang B; Jiang Y; Yang J; Zhou W; Yang T; Zhang R; Xu J; Guo H
BMC Urol; 2023 Jun; 23(1):104. PubMed ID: 37280589
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
11. Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer.
Chen L; Zhang M; Zhou J; Zhang L; Liang C
Cancer Med; 2022 Nov; 11(22):4374-4388. PubMed ID: 35535438
[TBL] [Abstract][Full Text] [Related]
12. Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma.
Zhao HB; Zeng YR; Han ZD; Zhuo YJ; Liang YK; Hon CT; Wan S; Wu S; Dahl D; Zhong WD; Wu CL
Cancer Sci; 2021 Oct; 112(10):4365-4376. PubMed ID: 34252262
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Nuclear Mitochondrial-Related Multi-Genes Signature to Predict the Prognosis of Bladder Cancer.
Jiang X; Xia Y; Meng H; Liu Y; Cui J; Huang H; Yin G; Shi B
Front Oncol; 2021; 11():746029. PubMed ID: 34692528
[TBL] [Abstract][Full Text] [Related]
14. Development of an autophagy-related gene expression signature for prognosis prediction in prostate cancer patients.
Hu D; Jiang L; Luo S; Zhao X; Hu H; Zhao G; Tang W
J Transl Med; 2020 Apr; 18(1):160. PubMed ID: 32264916
[TBL] [Abstract][Full Text] [Related]
15. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel five-gene immune-related risk model for the prognosis evaluation of prostate adenocarcinoma patients.
Fei H; Chen X
Am J Cancer Res; 2022; 12(5):2337-2349. PubMed ID: 35693084
[TBL] [Abstract][Full Text] [Related]
17. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of Autophagy-Related Gene Signature and Nomogram for Predicting Survival in Oral Squamous Cell Carcinoma.
Hou C; Cai H; Zhu Y; Huang S; Song F; Hou J
Front Oncol; 2020; 10():558596. PubMed ID: 33178587
[TBL] [Abstract][Full Text] [Related]
19. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma.
Tang B; Zhang X; Yang X; Wang W; Li R; Liu Y
Front Immunol; 2022; 13():1013248. PubMed ID: 36466855
[TBL] [Abstract][Full Text] [Related]
20. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
Front Oncol; 2022; 12():915662. PubMed ID: 36033441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]